Author avatar

Karen Pendergrass, Standards Team

About

Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.

Recent Posts

2024-06-20 12:21:53

Idiopathic

“Idiopathic” is a term used in medicine to describe a disease or condition that arises spontaneously or for which the cause is unknown.

2024-06-20 11:08:47

Scoliosis

Scoliosis, a spinal curvature over 10°, is influenced by gut microbiome variations, affecting spinal, respiratory, and cardiovascular health.

2024-06-15 16:44:04

Cholestyramine

Cholestyramine, a polymer resin, binds bile acids, toxins, and heavy metals, reducing cholesterol and fat absorption, while altering gut microbiome and aiding detoxification.

2024-05-23 11:15:09

Hyperbaric Oxygen Therapy (HBOT)

Hyperbaric Oxygen Therapy (BOT) involves breathing pure oxygen in a pressurized chamber, which increases the amount of oxygen dissolved in the blood and delivered to tissues.

2024-05-06 19:00:47

Estrogen

Estrogen is a steroid hormone primarily found in women, crucial for reproductive health, secondary sexual characteristics, and various physiological processes. It regulates menstrual cycles, supports pregnancy, and influences bone density and cardiovascular health. Dysregulation of estrogen levels can lead to various disorders and health complications.

2024-04-25 12:16:33

STOPs

A TOP (Suggested Termination Of Practices) is a recommendation that advocates for the discontinuation of certain medical interventions, treatments, or practices based on emerging evidence indicating that these may be ineffective, harmful, or counterproductive in the management of specific conditions.

2024-04-22 12:37:27

β-Glucuronidase

β-glucuronidase in the gut microbiome breaks down metabolites, drugs, and hormone conjugates like estrogen, aiding microbial energy use and nutrient cycling. Its activity influences drug efficacy and hormone levels, maintaining estrogen balance and impacting health. Disruption in this process can lead to estrogen-related diseases, such as gynecological cancers and menopausal syndrome, and increase colorectal cancer risks by reactivating carcinogens, highlighting its pivotal role in linking microbial actions to host physiological processes.

2024-04-21 12:06:50

Gallium

Gallium is studied for its unique antimicrobial and anticancer properties. It inhibits metalloproteinases, disrupts bacterial iron metabolism, and may enhance antibiotic efficacy, particularly against resistant strains. Gallium compounds show potential as non-traditional therapeutic agents in treating infections and inhibiting cancer cell invasion and metastasis.

2024-04-20 12:38:33

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation (MT) involves transferring fecal bacteria from a healthy donor to a patient to restore microbiome balance.

2024-04-20 11:24:58

Vaginal Microbiome Transplant (VMT)

Vaginal Microbiome Transplant (MT) involves transferring healthy vaginal flora from a donor to a recipient to treat conditions like recurrent bacterial vaginosis. It aims to restore balance in the vaginal microbiome, potentially offering a non-pharmacological treatment option for persistent gynecological disorders.